There remains valuable open space in the $15 billion retinal vascular diseases market, despite the availability of approved biologics and clinical trials of new exploratory technologies Efficacy Durability Gen 1.0 • Eylea • Lucentis • Biosimilars Gen 1.5 • Eylea HD • Vabysmo Implants Gene Therapies Approved mainstay biologics that provide: High Immediacy High Immediacy + Incremental Durability Exploratory technology-products in clinical trials designed for: High Durability High Immediacy + High Durability At the same time and in the same product A biologic that provides: 11